Drug Profile
Research programme: epithelial sodium channel inhibitors - Novartis
Alternative Names: ENaC inhibitorsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Novartis
- Class
- Mechanism of Action Epithelial sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cystic-fibrosis in United Kingdom